Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Surveillance Clear all
Terminated Phase 2 Interventional Accepts healthy volunteers

Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1

NCT03630809
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer, HER-2 Gene Amplification, HER2 Positive Breast Carcinoma, HER-2 Protein Overexpression, Breast Cancer, Male, Breast Cancer Female
Interventions
HER2 DC1 Vaccine
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 22, 2026, 8:24 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Kesimpta (Ofatumumab) Pregnancy Registry

NCT05634967
View directory record Official record
Conditions
Multiple Sclerosis, Pregnancy
Interventions
Kesimpta
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
725 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2033
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 22, 2026, 8:24 PM EDT
Recruiting No phase listed Observational

Twiist Postmarket Surveillance Study for Type 1 Diabetes

NCT07356089
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Type 1 Diabetes Mellitus
Interventions
twiist Automated Insulin Delivery System
Device
Lead sponsor
Deka Research and Development
Industry
Eligibility
6 Years and older
Enrollment
1,875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 22, 2026, 8:24 PM EDT
Completed Phase 1 Interventional

Phase I Pharmacokinetic and Tolerance Study of Ribavirin in Human Immunodeficiency Virus (HIV) - Infected Patients

NCT00000733
View directory record Official record
Conditions
HIV Infections
Interventions
Ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
2
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 22, 2026, 8:24 PM EDT
Terminated No phase listed Observational

Benralizumab Pregnancy Exposure Study

NCT03794999
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab-exposure, Exposure to other asthma medications
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 22, 2026, 8:24 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Trial on Rapid Immune Modulating Effects

NCT07206407
View directory record Official record
Conditions
Immune Surveillance
Interventions
Placebo, Nutraceutical blend
Dietary Supplement
Lead sponsor
Natural Immune Systems Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Klamath Falls, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 22, 2026, 8:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida

NCT04596579
View directory record Official record
Conditions
Coronavirus Infection
Interventions
SARS-CoV-2 Antibody Analysis, Weck-cel Swab Collection, Web Based Questionnaire
Diagnostic Test · Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
1,135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Oct 22, 2026, 8:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

EpiCor Clinical Study on Rapid Immune Modulating Effects

NCT05819424
View directory record Official record
Conditions
Immune Surveillance
Interventions
Yeast Fermentate (EpiCor)
Dietary Supplement
Lead sponsor
Cargill
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Klamath Falls, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 22, 2026, 8:24 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Clinical Proof-of-concept Study on Rapid Immune Modulating Effects

NCT05364710
View directory record Official record
Conditions
Immune Surveillance
Interventions
Transfer factor from colostrum ultrafiltrate
Dietary Supplement
Lead sponsor
Natural Immune Systems Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Klamath Falls, Oregon
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 22, 2026, 8:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acute Immune Modulation by Probiotic Strain

NCT06754228
View directory record Official record
Conditions
Immune Surveillance
Interventions
Probiotic Agent
Dietary Supplement
Lead sponsor
Natural Immune Systems Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Klamath Falls, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 22, 2026, 8:24 PM EDT
Completed Phase 1 Interventional

A Study of AS-101 in Patients With AIDS or AIDS Related Complex (ARC)

NCT00001006
View directory record Official record
Conditions
HIV Infections
Interventions
AS-101
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 22, 2026, 8:24 PM EDT
Completed Phase 4 Interventional Results available

Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis

NCT02092467
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
tofacitinib, adalimumab, etanercept
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
4,372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
142
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 22, 2026, 8:24 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Rapid Response of Stem Cells and Immune Cells for Efficacy

NCT07127705
View directory record Official record
Conditions
Stem Cell Surveillance
Interventions
Placebo, Chaga Mushroom, Ginseng extract, Olive extract, Potassium Hydrogen Glucarate
Dietary Supplement
Lead sponsor
Natural Immune Systems Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Klamath Falls, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 22, 2026, 8:24 PM EDT
Completed Phase 1 Interventional

A Clinical Trial To Evaluate the Toxicity and Antiviral Effects of a Range of Doses of Ampligen in p24 Antigen Positive HIV-Infected Patients With AIDS or ARC

NCT00000735
View directory record Official record
Conditions
HIV Infections
Interventions
Ampligen
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 22, 2026, 8:24 PM EDT
Completed No phase listed Observational

Asthma Surveillance and Education in Preschool Settings

NCT00201071
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 4 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 22, 2026, 8:24 PM EDT
Active, not recruiting Not applicable Interventional Results available

Testing a Novel Data-to-Suppression (D2S) Intervention Strategy in the Ryan White HIV/AIDS Program

NCT05140421
View directory record Official record
Conditions
Hiv
Interventions
Data to Suppression (D2S), Usual practice
Other
Lead sponsor
City University of New York
Other
Eligibility
Not listed
Enrollment
1,494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
27
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 22, 2026, 8:24 PM EDT
Completed Phase 2 Interventional

A Study of Tumor Necrosis Factor and Human Interferon-gamma in Patients With AIDS Related Complex

NCT00001004
View directory record Official record
Conditions
HIV Infections
Interventions
Tumor Necrosis Factor, Interferon gamma-1b
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 22, 2026, 8:24 PM EDT
Completed No phase listed Observational

Electronic Pharmacotherapy Risk Management

NCT00828490
View directory record Official record
Conditions
Asthma, Mental Health, Pain
Interventions
provider feedback, patient intervention, Process-level
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
Not listed
Enrollment
174,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 23, 2010 · Synced Oct 22, 2026, 8:24 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Trial: Rapid Immune Modulating Effects

NCT07195552
View directory record Official record
Conditions
Immune Surveillance
Interventions
Agaricus blazei, Reishi, Turkey Tail, Placebo
Dietary Supplement · Other
Lead sponsor
Natural Immune Systems Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Klamath Falls, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 22, 2026, 8:24 PM EDT
Terminated No phase listed Observational

Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance

NCT01156298
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 85 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2012 · Synced Oct 22, 2026, 8:24 PM EDT
Recruiting No phase listed Observational

The iLet Experience Study

NCT06891898
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
iLet Dosing Decision Software
Device
Lead sponsor
Beta Bionics, Inc.
Industry
Eligibility
6 Years and older
Enrollment
1,875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 22, 2026, 8:24 PM EDT
Completed No phase listed Observational

Prospective Maternal Surveillance of SSA (Sjögren Syndrome A) Positive Pregnancies Using a Hand-held Fetal Heart Rate Monitor

NCT02920346
View directory record Official record
Conditions
Sjogren's Syndrome, Neonatal Systemic Lupus Erythematosus, Fetal Heart Block Complete
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 22, 2026, 8:24 PM EDT
Completed No phase listed Observational

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

NCT02921828
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Not listed
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
1,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
No City Provided, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 22, 2026, 8:24 PM EDT
Not yet recruiting Phase 3 Interventional

PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study

NCT07670650
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
SAB-142, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
5 Years to 40 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 22, 2026, 8:24 PM EDT